Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -32% Improvement Relative Risk c19early.org/e Pourhoseingholi et al. Aspirin for COVID-19 LATE Is late treatment with aspirin beneficial for COVID-19? Prospective study of 2,468 patients in Iran (Feb - Jul 2020) Higher mortality with aspirin (p=0.036) Pourhoseingholi et al., Research Square, doi:10.21203/rs.3.rs-365321/v2 Favors aspirin Favors control
Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study
Pourhoseingholi et al., Research Square, doi:10.21203/rs.3.rs-365321/v2 (Preprint)
Pourhoseingholi et al., Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A.., Research Square, doi:10.21203/rs.3.rs-365321/v2 (Preprint)
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 2,468 hospitalized COVID-19 patients in Iran, showing higher mortality with aspirin treatment. IR.MUQ.REC.1399.013.
risk of death, 32.0% higher, HR 1.32, p = 0.04, treatment 71 of 290 (24.5%), control 268 of 2,178 (12.3%), adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pourhoseingholi et al., 26 May 2021, prospective, Iran, preprint, mean age 57.9, 11 authors, study period 2 February, 2020 - 20 July, 2020, average treatment delay 7.4 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study Mohamad Amin Pourhoseingholi Shahid Beheshti University of Medical Sciences Hosein Yousefi Qom University of Medical Science and Health Services Hassan Fatemi Manesh Qom University of Medical Science and Health Services Nima Najafian Motahaver Qom University of Medical Science and Health Services Zahra Heydari Qom University of Medical Science and Health Services Mehdi Azizmohammad Looha Shahid Beheshti University of Medical Sciences Nazanin Taraghikhah Shahid Beheshti University of Medical Sciences Maryam Yazdi Qom University of Medical Science and Health Services Zahra Salami Qom University of Medical Science and Health Services Elmira Moallemi Qom University of Medical Science and Health Services Seyed Hasan Adeli (  adeli@muq.ac.ir ) Qom University of Medical Science and Health Services Research Article Keywords: COVID-19, Pandemic, Iran, Risk factor, Cohort Posted Date: May 26th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-365321/v2 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/25 Abstract The outbreak of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) dates back to December 2019 in China. Iran has been one of the most virus inflicted countries. The aim of this study was to report demographics, signs and symptoms, laboratory findings, therapeutic approaches, and outcomes. This observational cohort study was performed from 20th February 2020 to 20th July 2020. Patients’ information was recorded in their medical files. Multivariable analysis was performed to assess demographics, signs and symptoms, paraclinical data, treatments, outcomes of disease, and finding the risk factors of death subject to COVID-19. Of all 2468 participants, the mean age was 57.9±17.6 years and 56.8% of patients were male. The most significant comorbidities were seen among those who have Hypertension and Diabetes Mellitus. 14.42% were admitted to ICU, and 17.2% died in hospital. The significant risk factors of death were ageing, male gender, HTN, CHF, CVA, CKD, increasing ESR, PT, WBC, liver function tests, and decreasing Oxygen saturation. Incontinent results in the case of COVID-19 outcomes and deathrelated risk factors attribute to marked differences in demographics and health care systems. The patients with hazardous risk factors must be detected urgently and monitored closely to save more lives.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit